Anti-angiogenic Therapy
Anti-angiogenic Therapy - Related Videos
10:04
The Aortic Ring Co-culture Assay: A Convenient Tool to Assess the Angiogenic Potential of Mesenchymal Stromal Cells In Vitro
0 Views •
Cited by 12 •
2017
Here, we present a novel application of the aortic ring assay where prelabelled mesenchymal cells are co-cultured with rat aorta-derived endothelial networks. This novel method allows visualization of Mesenchymal Stromal Cells (MSCs) homing and integration with endothelial networks, quantification of network properties, and evaluation of MSC immunophenotypes and gene expression.
04:21
Generating Anti-Angiogenic Tumor-Associated Neutrophils
0 Views •
2025
This video demonstrates an assay to generate anti-angiogenic tumor-associated neutrophils (TANs). Upon taking a murine melanoma tumor containing pro-angiogenic TANs, the single cells are isolated using fluorescence-activated cell sorting (FACS) and treated with an inhibitor of nicotinamide phosphoribosyl transferase (NAMPT) to reduce the capacity to stimulate angiogenesis.
13:21
Antibody Generation: Producing Monoclonal Antibodies Using Hybridomas
0 Views •
2023
Source: Frances V. Sjaastad1,2, Whitney Swanson2,3, and Thomas S. Griffith1,2,3,4 1 Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455 2 Center for Immunology, University of Minnesota, Minneapolis, MN 55455 3 Department of Urology, University of Minnesota, Minneapolis, MN 55455 4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455 Polyclonal antibodies are defined as a collection of antibodies directed against...
01:10
Antibody Structure
0 Views •
2019
Overview Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding. The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains Antibodies consist of four polypeptide chains: two identical heavy...
12:55
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
0 Views •
Cited by 33 •
2015
A method is described with visual accompaniment for conducting scalable, high throughput selections from phage-displayed combinatorial synthetic antibody libraries against hundreds of antigens simultaneously. Using this parallel approach, we have isolated antibody fragments that exhibit high affinity and specificity for diverse antigens that are functional in standard immunoassays.
FAQs
By blocking VEGF or its receptors, anti-angiogenic therapy interrupts signals that normally stimulate endothelial cells, the cells lining blood vessels. This reduces their proliferation, migration, and vessel sprouting, weakening the formation of new vascular networks. The mechanism matters because it targets signaling events that support abnormal vessel development rather than only describing a change in blood supply.
The therapeutic effect depends on which part of the VEGF signaling pathway is inhibited. Blocking VEGF removes a growth stimulus, whereas receptor blockade prevents endothelial cells from receiving that stimulus. Both approaches can disrupt the coordinated cellular behaviors required for vessel formation, but the distinction helps researchers compare mechanisms and study how vascular signaling shapes disease progression.
Angiogenic signaling is not exclusive to diseased tissue. Normal tissue repair and cardiovascular function also rely on these signals, so suppressing them can create concerns beyond the intended disease target. Treatment assessment therefore requires careful monitoring rather than focusing only on whether abnormal vessel growth or tumor-related vascular support has decreased.
Clinical use centers on conditions in which abnormal vascular support contributes to disease. In tumors, reducing blood supply can limit growth; in retinal disorders, suppressing abnormal vessel formation can help manage the disease. These applications share a vascular target but involve different tissues, allowing the same therapeutic principle to address distinct medical problems.
Monitoring should assess both intended vascular effects and possible consequences for normal physiology. In oncology, assessment can consider whether reduced blood supply corresponds with limited tumor growth; in retinal disease, it can consider control of abnormal vessel formation. Cardiovascular function and tissue repair also warrant attention because angiogenic signaling supports both.
Beyond immediate treatment, anti-angiogenic therapy provides a framework for studying tumor biology, vascular remodeling, and drug resistance. Researchers also examine combination treatments, asking how vascular-targeted intervention interacts with other therapeutic strategies. These investigations can clarify why limiting vessel formation may not fully control disease and can guide efforts to improve treatment design.